Braavos Investment Advisers
London investor backing companies built on scientific breakthroughs, with a particular focus on University of Oxford spinouts.
- Venture capital
- London
- Type
- Venture capital
- Based in
- London
- Stages
- Seed, Series A, Series B+
- Sector focus
- Biotech & Life Sciences, Healthtech, Deeptech, Climate & Energy
- Fund size
- Undisclosed
- Website
- braavos.uk
Braavos Investment Advisers, trading as Braavos Capital, is a London-based investor in companies founded on scientific and technological breakthroughs, with a particular focus on those linked to the University of Oxford. It provides founders with capital, networks and help with hiring. Its portfolio includes vaccine developers SpyBiotech and Vaccitech, the diagnostics company Osler Diagnostics, the crop-engineering business Wild Bioscience and the fusion energy developer First Light Fusion. It is also a partner of Oxford Science Enterprises. Its general partners are Magda Wierzycka and Andre Crawford-Brunt.
← All investors · Is this your organisation? Request an update
More investors in the directory
The Craftory
Purpose-driven consumer packaged goods brands with category-changing potential
Symvan Capital
EIS and SEIS funds backing B2B SaaS and technology companies from seed to exit
Grafton Capital
Growth capital for European software, AI and tech-enabled businesses
Blackfinch Ventures
EIS and VCT investment in early and growth-stage UK technology businesses
The Conduit Connect
Impact-led UK startups from pre-seed to Series A in climate, health and financial resilience
TrueSight Ventures
Angel-sized cheques at pre-seed and seed, sector-agnostic, into technology companies
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.